SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.